Shots:

• Henlius reported that TGA has approved the filing of clinical trial for HLX04-O to treat wet-AMD
• The two part P-III global study is expected to be initiated in Australia to further evaluate the efficacy & safety of HLX04-O (vitreous injection) in treatment of wAMD
• HLX04-O is a recombinant anti-VEGF humanized mAb ophthalmic injection and has the potential to be one of the first bevacizumab approved for ophthalmic diseases

 ­ Ref: Henlius | Image: Henlius